Calyx and Invicro are now Perceptive
Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
Farhan A. Syed, Ph.D., David Bennett, Ph.D., Michael O’Connor, Ph.D., Gabriele Pradella, and Sarah Warner, Ph.D.
Presented at the American College of Rheumatology Annual Convergence, 2018
Phase 2 and phase 3 trials in Axial Spondyloarthritis (AxSpA) require the assessment of the sacro-iliac joint (SIJ) either by X-ray or MRI or both in conjunction to establish if the disease is non-radiographic (nr- AxSpA) or radiographic ankylosing spondylitis (AS).
Therefore, for prospective trial design it is important to understand the percentages of subjects likely to be deemed eligible by central imaging review and how many subjects will screen-fail for either AS (mNY+) or nr-AxSpA (mNY-).
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
"*" indicates required fields
Δ
